

## **Tata Chemicals**

Estimate change	$\leftarrow$
TP change	1
Rating change	<b>—</b>
-	

Bloomberg	TTCH IN
Equity Shares (m)	255
M.Cap.(INRb)/(USDb)	239.8 / 2.8
52-Week Range (INR)	1247 / 756
1, 6, 12 Rel. Per (%)	2/-8/-11
12M Avg Val (INR M)	1157

#### Financials & Valuations (INR b)

Y/E Mar	2025	2026E	2027E
Sales	150.1	156.6	167.7
EBITDA	20.8	25.9	31.9
PAT	4.2	9.1	14.0
EBITDA (%)	13.8	16.5	19.1
EPS (INR)	16.5	35.8	54.8
EPS Gr. (%)	(54.4)	117.4	53.0
BV/Sh. (INR)	847	871	911
Ratios			
Net D/E	0.2	0.2	0.1
RoE (%)	1.9	4.2	6.2
RoCE (%)	2.8	4.8	6.2
Valuations			
P/E (x)	57.1	26.3	17.2
EV/EBITDA (x)	14.3	11.2	8.5
Div Yield (%)	1.2	1.3	1.6
FCF Yield (%)	(1.5)	6.0	10.2

#### **Shareholding Pattern (%)**

As On	Jun-25	Mar-25	Jun-24
Promoter	38.0	38.0	38.0
DII	22.7	22.0	20.0
FII	12.8	13.3	13.8
Others	26.5	26.7	28.3

CMP: INR941 TP: INR970 (+3%) Neutral

# India/UK basic chemistry and specialty products drive operating performance

#### Operating performance beats our expectations

- Tata Chemicals' (TTCH) 1QFY26 consolidated EBITDA grew 13% YoY, led by lower power and fuel costs (reduction in coal prices) and cost rationalization initiatives. India/UK/Rallis delivered a healthy performance (EBITDA up 15%/78%/56%), while US/TCAHL showed a subdued performance (EBITDA down 5%/32%). Revenue declined marginally by 2% YoY due to flat volume (higher volume in India offset by lower volume in the US/UK/Kenya).
- The soda ash demand-supply balance continues to be soft in the short-term owing to tariff changes and excess supply across regions. However, we believe the company will see a gradual improvement on the back of cost rationalization initiatives, soft input prices and capacity additions.
- We largely maintain our FY26/FY27 EBITDA estimates despite increasing Rallis India and UK estimates which largely offsets the reduction in estimates of Africa and US business. Reiterate Neutral with an SoTP-based TP of INR970.

#### Operating performance - a mixed bag

- TTCH reported total revenue of INR37.2b (est. INR39.8b) in 1QFY26, down 2% YoY, due to a slight decline in soda ash volumes (down 3%). Sodium bicarbonate/salt volumes grew 8%/1%. EBITDA margin expanded 230bp YoY to 17.5% (est. 14.3%), led by lower variable costs and favorable operating leverage. EBITDA stood at INR6.5b (est. INR5.7b), up 13% YoY.
- TTCH reported an adj. net profit of INR2.5b vs. ~INR1.4b in 1QFY25 (est. ~INR1.8b)
- Basic Chemistry Products business was down 8% YoY at INR27.2b. EBIT was flat YoY at INR3b. EBIT margins stood at 11%.
- Specialty Products business grew 22% YoY to INR10b. EBIT was up 85% YoY at INR3b. EBIT margins stood at 11%.
- India standalone/Rallis revenue grew ~12%/22% YoY to INR11.7b/INR9.6b. TCNA/TCEHL/TCAHL fell 6%/28%/9% YoY to INR12.1b/INR3.8b/INR1.3b.
- EBITDA for India standalone/TCEHL/Rallis grew 15%/78%/56% to INR2.7b/INR320m/INR1.5b, while the same for TCNA/TCAHL declined 5%/32% YoY to INR1.9b/INR1.7b.
- EBITDA/MT of TCNA remained flat YoY at ~USD40.6, while for TCAHL it declined 26% YoY to USD32. EBITDA margin for India standalone expanded 70bp YoY to 23.1%.

#### Highlights from the management commentary

Demand-supply scenario: The demand-supply balance continues to be soft, coupled with uncertainties in soda ash trade due to tariff changes. Demand is not a concern, excess supply of unviable capacities remains a major concern. A large unit in China may begin a long-term maintenance haul – if this happens, the dynamics will turn favorable.

Research Analyst: Sumant Kumar (Sumant.Kumar@MotilalOswal.com) | Meet Jain (Meet.Jain@MotilalOswal.com) | Research Analyst: Nirvik Saini (Nirvik.Saini@MotilalOswal.com) | Yash Darak (Yash Darak@ MotilalOswal.com)



- European business: Margin improvement was led by a better product mix.

  Going forward, the pharma salt business and inhouse manufacturing of CO2 would be the key growth drivers. The company expects the bicarb business to break even this year, as TTCH has to recalibrate the business after the cessation of soda ash capacity. Additionally, the cessation of the Lostock business led to a decrease in costs.
- Capex: TTCH has guided for an annual maintenance capex of INR10b for FY26.

  No major expansion is expected after the expansion in Kenya (~50kpta capacity).

  Trial runs of the said capacity are going on, and it is expected to be commissioned in 2HFY26.

#### Valuation and view

- TTCH is expected to benefit from near-term tailwinds of a reduction in coal prices, capacity additions in Kenya, and growth drivers from the European business. Further, its strategic focus on specialty products positions TTCH well for long-term growth once global demand recovers.
- We expect the company will see a gradual improvement on the back of cost rationalization initiatives, soft input prices and capacity additions.
- We largely maintain our FY26/FY27 EBITDA estimates despite increasing Rallis India and UK estimates which largely offsets the reduction in estimates of Africa and US business. Reiterate Neutral with an SoTP-based TP of INR970.

Consolidated - Quai	rterly Ear	ning Mod	del									(INRm)
Y/E March		FY	25			FY	<b>26</b> E		FY25	FY26E	FY26E	Var
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE			1Q	%
Net Sales	37,890	39,990	35,900	35,090	37,190	42,987	37,847	38,604	1,48,870	1,56,628	39,856	-7
YoY Change (%)	-10.2	0.0	-3.8	1.0	-1.8	7.5	5.4	10.0	-3.5	5.2	5.2	
Total Expenditure	32,150	33,810	31,560	31,820	30,700	36,485	31,642	31,913	1,29,340	1,30,740	34,143	
EBITDA	5,740	6,180	4,340	3,270	6,490	6,502	6,205	6,691	19,530	25,888	5,713	14
Margins (%)	15.1	15.5	12.1	9.3	17.5	15.1	16.4	17.3	13.1	16.5	14.3	
Depreciation	2,730	2,770	2,800	2,930	2,800	2,850	2,950	3,050	11,230	11,650	2,940	
Interest	1,330	1,450	1,480	1,370	1,470	1,200	1,100	950	5,630	4,720	1,150	
Other Income	470	1,080	280	420	960	1,000	311	484	2,250	2,755	522	
PBT before EO	2,150	3,040	340	-610	3,180	3,452	2,466	3,175	4,920	12,273	2,145	
expense	2,130	3,040	340	-010	3,100	3,432	2,400	3,173	4,320	12,273	2,143	
Extra-Ord expense	0	0	700	550	0	0	0	0	1,250	0	0	
PBT	2,150	3,040	-360	-1,160	3,180	3,452	2,466	3,175	3,670	12,273	2,145	
Tax	940	810	170	-250	440	846	604	778	1,670	2,668	525	
Rate (%)	43.7	26.6	-47.2	21.6	13.8	24.5	24.5	24.5	45.5	21.7	24.5	
MI & Profit/Loss of	-140	290	0	-170	220	319	0	-64	-20	475	-208	
Asso. Cos.	-140	230	0	-170	220	319	<u> </u>	-04	-20	4/3	-200	
Reported PAT	1,350	1,940	-530	-740	2,520	2,287	1,862	2,461	2,020	9,130	1,827	
Adj PAT	1,350	1,940	-5	-328	2,520	2,287	1,862	2,461	2,958	9,130	1,827	38
YoY Change (%)	-73.8	-44.8	-100.3	-68.7	86.7	17.9	-37,336.5	-851.5	-67.9	208.7	35.4	
Margins (%)	3.6	4.9	0.0	-0.9	6.8	5.3	4.9	6.4	2.0	5.8	4.6	




**Key Performance Indicators** 

Y/E March		FY2	5			FY26	SE .		FY25	FY26E
Consolidated	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE		
Sales Volume (000'MT)										
North America	588	632	559	586	542	628	581	609	2,365	2,360
Europe	148	144	138	118	84	100	97	91	548	371
Africa	69	77	61	73	62	84	70	79	280	295
EBITDA/MT										
North America (USD)	40.4	42.1	30.9	15.7	40.6	40.0	45.0	47.0	32.5	43.2
Europe (GBP)	11.8	17.4	6.9	-22.1	32.5	25.0	30.0	34.7	4.8	30.4
Africa (USD)	43.4	66.6	42.7	83.6	32.1	87.0	88.0	90.0	60.1	76.5
Cost Break-up										
RM Cost (% of sales)	21.1	21.4	14.3	20.2	19.7	20.7	14.5	19.1	19.3	18.6
Staff Cost (% of sales)	12.6	12.5	14.7	13.8	13.9	11.9	13.6	13.2	13.4	13.1
Power and Fuel Cost (% of sales)	14.4	14.8	19.2	16.9	12.2	14.6	18.5	15.9	16.3	15.3
Freight and Distribution Cost (% of	17.6	17.2	18.0	20.9	18.9	18.5	17.0	16.5	10.4	177
sales)	17.6	17.2	18.0	20.9	18.9	18.5	17.0	10.5	18.4	17.7
Other Cost (% of sales)	19.2	18.6	21.7	18.8	17.8	17.6	19.2	17.9	19.5	18.1
Gross Margins (%)	78.9	78.6	85.7	79.8	80.3	79.3	85.5	80.9	80.7	81.4
EBITDA Margins (%)	15.1	15.5	12.1	9.3	17.5	16.7	17.2	17.4	13.1	17.2
EBIT Margins (%)	7.9	8.5	4.3	1.0	9.9	9.5	9.2	9.3	5.6	9.5




### **Key exhibits**

**Exhibit 1: Consolidated revenue trend** 




Sources: Company reports, MOFSL

**Exhibit 2: Consolidated EBITDA trend** 



Sources: Company reports, MOFSL

**Exhibit 3: Consolidated adjusted PAT trend** 



Sources: Company reports, MOFSL

Exhibit 4: Consolidated segmental revenue

Exhibit 4. Consolidated segmental revenue													
INR m	1QFY25	4QFY25	1QFY26	%YoY	%QoQ								
Revenue													
Basic Chemistry products	29,720	30,370	27,220	-8%	-10%								
Specialty products	8,190	4,720	10,010	22%	112%								
Less: Inter-segment revenue	20	10	40										
Add: Unallocated	-	10	-										
Total revenue	37,890	35,090	37,190	-2%	6%								

**Exhibit 5: Consolidated segmental EBIT** 

INR m	1QFY25	4QFY25	1QFY26	%YoY	%QoQ
EBIT	•	,	•		, ,
Basic Chemistry products	2,980	840	3,000	1%	257%
Margin	10.0%	2.8%	11.0%		
Specialty products	600	-630	1,110	85%	-276%
Margin	7.3%	-13.3%	11.1%		
Total EBIT	3,580	210	4,110	15%	1857%
Less: Finance Cost	1,330	1,370	1,470		
Less: Unallocated (income)/expense	100	-	-540		
PBT	2,150	-1,160	3,180	48%	-374%

Sources: Company reports, MOFSL



**Exhibit 6: Standalone operational performance trend** 

INRm	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	%YoY	%QoQ
Soda Ash sales volume ('000MT)	155	161	168	157	167	159	181	210	198	19%	-6%
Sodium Bicarbonate sales volume ('000MT)	29	30	32	34	32	33	41	42	44	38%	5%
Salt sales volume ('000MT)	312	338	324	371	326	322	354	346	335	3%	-3%
Realization-Basic Chemistry Products (INR/MT)	21,835	19,282	20,248	18,772	19,257	18,969	19,549	19,682	19,497	1%	-1%
Net sales	11,350	10,660	10,930	10,900	10,470	10,090	11,660	12,190	11,690	12%	-4%
EBITDA	2,890	1,880	2,060	1,920	2,350	1,440	2,090	2,300	2,700	15%	17%
EBITDA (%)	25.5%	17.6%	18.8%	17.6%	22.4%	14.3%	17.9%	18.9%	23.1%	65	423
PBT	4,060	2,730	1,400	1,970	3,220	1,170	830	1,200	3,320	3%	177%
PAT	3,280	1,595	1,150	2,170	2,560	990	720	970	3,070	20%	216%

Sources: Company reports, MOFSL

**Exhibit 7: Performance trend in the North American operations** 

INR m	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	%YoY	%QoQ
Soda Ash utilization (%)	84%	86%	83%	99%	93%	100%	88%	92%	85%	-724	-693
Sales volume ('000MT)	535	545	529	626	588	632	559	586	542	-8%	-8%
Realization (INR/MT)	27,738	24,330	23,819	20,879	21,786	22,009	22,773	22,457	22,288	2%	-1%
Realization (USD/MT)	337	295	286	252	261	263	270	259	261	0%	1%
EBITDA/MT (USD)	108	71	33	28	40	42	31	16	41	0%	158%
Net sales	14,840	13,260	12,600	13,070	12,810	13,910	12,730	13,160	12,080	-6%	-8%
EBITDA	4,760	3,190	1,450	1,470	1,980	2,230	1,460	800	1,880	-5%	135%
EBITDA (%)	32.1%	24.1%	11.5%	11.2%	15.5%	16.0%	11.5%	6.1%	15.6%	11	948
PAT	2,920	1,390	110	150	390	650	20	-440	430	10%	-198%

Sources: Company reports, MOFSL

**Exhibit 8: Performance trend in the European operations** 

INR m	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	%YoY	%QoQ
Soda Ash volume ('000MT)	57	55	50	46	47	46	45	33	0	-100%	-100%
Sodium Bicarbonate volume ('000MT)	24	24	23	23	25	23	22	15	12	-52%	-20%
Salt ('000MT)	72	77	83	75	76	75	71	70	72	-5%	3%
Total sales volume ('000MT)	153	156	156	144	148	144	138	118	84	-43%	-29%
Realization (INR/MT)	42,484	38,974	38,077	38,403	35,473	36,875	38,696	35,339	44,881	27%	27%
Realization (GBP/MT)	418	382	370	374	344	356	371	329	383	11%	16%
EBITDA/MT (GBP)	73	72	36	43	12	17	7	-22	33	176%	-247%
Net sales	6,500	6,080	5,940	5,530	5,250	5,310	5,340	4,170	3,770	-28%	-10%
EBITDA	1,130	1,140	570	630	180	260	100	-280	320	78%	-214%
EBITDA (%)	17.4%	18.8%	9.6%	11.4%	3.4%	4.9%	1.9%	-6.7%	8.5%	506	1,520
PAT	400	330	-240	-780	-600	-590	-780	-1,010	-310	-48%	-69%

Sources: Company reports, MOFSL


**Exhibit 9: Performance trend in African operations** 

INR m	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	%YoY	%QoQ
Soda ash utilization (%)	63%	70%	73%	73%	79%	88%	70%	83%	71%	-800	-1,257
Sales volume ('000MT)	55	61	64	64	69	77	61	73	62	-10%	-15%
Realization (INR/MT)	31,818	25,574	25,469	22,813	21,449	21,818	22,295	21,644	21,613	1%	0%
Realization (USD/MT)	387	310	306	275	257	260	264	249	253	-2%	1%
EBITDA/MT (USD)	142	101	105	73	43	67	43	84	32	-26%	-62%
Net sales	1,750	1,560	1,630	1,460	1,480	1,680	1,360	1,580	1,340	-9%	-15%
EBITDA	640	510	560	390	250	430	220	530	170	-32%	-68%
EBITDA (%)	36.6%	32.7%	34.4%	26.7%	16.9%	25.6%	16.2%	33.5%	12.7%	-421	-2,086
PAT	410	350	230	340	330	400	180	270	180	-45%	-33%

Sources: Company reports, MOFSL



#### Exhibit 10: Sales volume trends across geographies



Sources: Company, MOFSL

#### **Exhibit 11: Strategic priorities**





### Focus Areas & Projects

- ESG Rating maintained at "Adequate" by CRISIL
- Biogenic fuel (biomass) trials progressing in India
- 5 MW Solar plant and Electric Calciner commissioned in Magadi
- Cumulative capacity to 791.55 million cubic feet (MCFT) of water harvesting capacity created
- 7 Whale Sharks have been rescued and released (Cumulative 986 since start of the project)

Sources: Company reports, MOFSL





### Highlights from the management commentary

### **Demand-supply scenario**

- The demand-supply balance continues to be soft, coupled with uncertainties in soda ash trade due to tariff changes.
- Soda ash markets continue to face oversupply, with high inventory levels in most regions. Prices continued to weaken during 1QFY26. Overall global demand is estimated to be flat in the near term.
- The medium- to long-term trend is positive, driven by sustainability applications (Solar PV + EV growth), even with short-term margin challenges.
- Lower YoY revenue in 1QFY26 was attributed to lower realization due to pricing pressure in all regions and lower volumes mainly on account of Lostock cessation.

#### India

- Performance was better this quarter due to operational efficiency.
- The company expects similar volumes in 2Q.
- Variable costs were down this quarter due to higher volumes. Also, the business enjoyed operating leverage.
- Soda ash pricing in India is set quarterly or semi-annually.

#### **North America**

- Exports to Asia continued to be under price pressure.
- Exports were impacted by the spill over (~45ktpa) of shipments to next quarter.
- Better margins were attributed to a volume mix greater share of domestic vs. export. This will normalize with a spillover in the next quarter and lower fixed costs this quarter.
- Domestic market is carried on an annual contract basis, so prices only change annually.

#### **Europe**

- Margin improvement was led by the product mix.
- There are two drivers for margin expansion: The company has started buying Inhouse CO2 this quarter rather than purchasing it externally, resulting in cost savings.
- Secondly, pharma-grade plant products are being tested with customers. This is expected to be started in 2HFY26.
- Management expects the bicarb business to break even this year as TTCH has to recalibrate the business after the cessation of soda ash capacity.
- The company expects to see sequential improvement going ahead and by 4Q, it can see a normalized business run rate.
- Pricing contracts are annually set.

#### **Africa**

- Volumes were lower due to a delay in shipments to Southeast Asia (as requested by customers).
- No major expansion is expected after the expansion in Kenya (~50kpta capacity).
   Trial runs of the said capacity are going on, and it is expected to be commissioned in 2HFY26.



Margins are expected to come back to normal levels.

#### Other

- Growth in Rallis was led by the crop care and the seeds business.
- Other income included INR750m of tax refund with interest.
- The current tax rate was a one-off and cannot be considered going forward.
- The company has guided for an annual maintenance capex of INR10b for FY26.

#### Valuation and view

- TTCH is expected to benefit from near-term tailwinds of a reduction in coal prices, capacity additions in Kenya, and growth drivers from the European business. Further, its strategic focus on specialty products positions TTCH well for long-term growth once global demand recovers.
- We expect the company will see a gradual improvement on the back of cost rationalization initiatives, soft input prices and capacity additions.
- We largely maintain our FY26/FY27 EBITDA estimates despite increasing Rallis India and UK estimates which largely offsets the reduction in estimates of Africa and US business. Reiterate Neutral with an SoTP-based TP of INR970.

**Exhibit 12: Valuation methodology** 

Methodology	Metrics	FY27	Multiple (x)	EV/ MCAP (INR m)
EV/EBITDA (x)	EBITDA	13,113	8	1,04,641
EV/EBITDA (x)	EBITDA	10,714	7	74,998
EV/EBITDA (x)	EBITDA	3,987	7	27,910
				2,07,549
20% discount to Current MCAP	Attributable Mcap	69,523	0.8	30,590
				2,38,139
				40,043
				13,260
				11,980
				21,316
	Мсар	66,316	0.8	53,053
				2,47,226
				255
				970
	EV/EBITDA (x) EV/EBITDA (x) EV/EBITDA (x) 20% discount to	EV/EBITDA (x) EBITDA  EV/EBITDA (x) EBITDA  EV/EBITDA (x) EBITDA  20% discount to Current MCAP  Attributable Mcap	EV/EBITDA (x) EBITDA 13,113  EV/EBITDA (x) EBITDA 10,714  EV/EBITDA (x) EBITDA 3,987  20% discount to Current MCAP Attributable Mcap 69,523	EV/EBITDA (x) EBITDA 13,113 8  EV/EBITDA (x) EBITDA 10,714 7  EV/EBITDA (x) EBITDA 3,987 7  20% discount to Current MCAP Attributable Mcap 69,523 0.8

Source: MOFSL

**Exhibit 13: Changes to our earnings estimates** 

Earnings Change	o	Old		ew	Change		
(INR m)	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E	
Revenue	1,52,487	1,62,725	1,56,628	1,67,664	3%	3%	
EBITDA	25,685	31,438	25,888	31,947	1%	2%	
Adj. PAT	8,942	13,923	9,130	13,965	2%	0%	
EPS	35	55	36	55	2%	0%	

Source: MOFSL

26 July 2025



**Appl. of Funds** 

### **Financials and valuations**

Consolidated - Income Statement									(INRb
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Total Income from Operations	103.4	103.6	102.0	126.2	167.9	154.2	150.1	156.6	167.7
Change (%)	0.7	0.2	-1.5	23.7	33.0	-8.1	-2.7	4.3	7.0
Total Expenditure	85.6	84.1	87.0	103.2	129.7	125.7	129.3	130.7	135.7
% of Sales	82.8	81.2	85.3	81.7	77.2	81.5	86.2	83.5	80.9
EBITDA	17.8	19.5	15.0	23.0	38.2	28.5	20.8	25.9	31.9
Margin (%)	17.2	18.8	14.7	18.3	22.8	18.5	13.8	16.5	19.1
Depreciation	5.7	6.7	7.6	8.1	8.9	9.8	11.2	11.7	12.3
EBIT	12.1	12.8	7.4	15.0	29.3	18.7	9.5	14.2	19.6
Int. and Finance Charges	3.5	3.4	3.7	3.0	4.1	5.3	5.6	4.7	2.8
Other Income	4.1	3.1	2.3	2.6	2.2	2.9	2.3	2.8	3.0
PBT bef. EO Exp.	12.7	12.5	6.1	14.5	27.4	16.2	6.2	12.3	19.8
EO Items	0.7	0.0	0.0	-0.3	-0.2	-8.5	-1.3	0.0	0.0
PBT after EO Exp.	13.4	12.5	6.1	14.3	27.2	7.7	4.9	12.3	19.8
Total Tax	2.7	2.2	2.0	2.7	2.9	3.8	1.7	2.7	4.8
Tax Rate (%)	20.5	17.5	32.5	18.7	10.6	49.4	34.0	21.7	24.5
MI & Profit/Loss of Asso. Cos.	1.3	2.3	1.5	-0.8	1.2	1.1	0.0	0.5	1.0
Reported PAT	11.6	70.1	2.6	12.4	23.2	2.8	3.3	9.1	14.0
Adjusted PAT	10.9	70.1	2.6	12.7	23.4	11.3	4.5	9.1	14.0
Consolidated - Balance Sheet									(INRb)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6	2.6
Total Reserves	120.9	126.4	140.4	180.0	194.7	219.9	213.4	219.3	229.5
Net Worth	123.4	129.0	142.9	182.5	197.2	222.4	215.9	221.9	232.0
Minority Interest	29.1	7.6	8.5	9.0	9.2	8.7	9.1	11.1	13.3
Total Loans	61.4	77.0	69.3	70.3	63.0	55.6	63.0	54.5	40.0
Lease liability	0.0	1.9	1.9	1.4	1.4	3.9	6.5	6.5	6.5
Deferred Tax Liabilities	13.0	14.4	15.7	20.4	19.4	23.8	25.4	25.4	25.4
Capital Employed	227.0	229.9	238.4	283.5	290.1	314.4	320.0	319.4	317.2
Gross Block	138.1	161.5	168.2	183.5	201.6	218.7	246.8	268.0	277.1
Less: Accum. Deprn.	21.5	28.1	35.7	43.8	52.7	62.5	73.7	85.4	97.7
Net Fixed Assets	116.6	133.3	132.4	139.7	148.9	156.2	173.1	182.6	179.4
Goodwill on Consolidation	18.6	19.5	19.2	19.7	21.6	21.9	22.5	22.5	22.5
Capital WIP	7.7	8.4	10.9	16.7	24.1	22.2	19.1	7.9	3.8
Current Investments	22.5	16.0	15.6	13.3	12.7	6.2	8.1	8.1	8.1
Total Investments	56.4	43.1	58.7	77.4	75.4	98.2	92.2	92.2	92.2
Curr. Assets, Loans&Adv.	69.6	72.6	62.1	84.9	80.9	69.1	71.0	71.7	80.2
Inventory	17.3	18.7	16.9	22.9	25.3	25.2	25.6	23.9	24.8
Account Receivables	14.5	15.8	14.0	19.3	26.3	19.0	19.0	20.6	22.0
Cash and Bank Balance	19.5	20.8	14.1	13.1	6.7	6.5	6.2	6.9	13.3
Loans and Advances	18.3	17.3	17.2	29.6	22.7	18.4	20.2	20.4	20.1
Curr. Liability & Prov.	42.1	47.0	45.0	54.9	60.7	53.1	57.8	57.6	60.8
Account Payables	14.8	16.3	16.8	24.4	26.0	23.7	25.1	23.1	24.8
Other Current Liabilities	9.5	11.4	8.5	13.9	16.7	12.5	16.2	17.2	17.6
	0.0		0.0	_0.0					_,
	17.8	19.3	19.6	16.5	18.1	17.0	16.6	17.2	18 4
Provisions Net Current Assets	17.8 <b>27.6</b>	19.3 <b>25.6</b>	19.6 <b>17.1</b>	16.5 <b>30.1</b>	18.1 <b>20.2</b>	17.0 <b>15.9</b>	16.6 <b>13.1</b>	17.2 <b>14.2</b>	18.4 <b>19.</b> 4

26 July 2025 9

238.4

283.5

290.1

314.4

320.0

319.4

317.2

227.0

229.9



### **Financials and valuations**

Ratios									
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Basic (INR)									
EPS	34.5	31.7	10.1	49.3	91.5	36.1	16.5	35.8	54.8
Cash EPS	56.8	57.8	39.9	81.0	126.5	74.6	60.6	81.5	103.2
BV/Share	484.3	506.1	560.8	716.3	773.9	872.8	847.4	870.8	910.6
DPS	12.5	11.0	10.0	12.5	17.5	15.0	11.0	12.5	15.0
Payout (%)	42.0	42.7	122.3	31.7	19.2	135.5	85.9	34.9	27.4
Valuation (x)									
P/E	27.3	29.8	93.6	19.1	10.3	26.1	57.1	26.3	17.2
Cash P/E	16.6	16.3	23.6	11.6	7.4	12.6	15.6	11.6	9.1
P/BV	1.9	1.9	1.7	1.3	1.2	1.1	1.1	1.1	1.0
EV/Sales	2.8	2.8	2.8	2.3	1.7	1.9	2.0	1.9	1.6
EV/EBITDA	16.2	14.8	19.2	12.7	7.7	10.2	14.3	11.2	8.5
Dividend Yield (%)	1.3	1.2	1.1	1.3	1.9	1.6	1.2	1.3	1.6
FCF per share	19.7	-16.3	45.0	-29.7	9.5	37.7	-14.5	56.6	96.1
Return Ratios (%)	13.7	10.5	13.0	23.7	3.3	37.7	11.5	30.0	30.1
RoE	7.5	6.4	1.9	7.7	12.3	4.4	1.9	4.2	6.2
RoCE	7.2	6.7	3.1	6.1	11.0	4.0	2.8	4.8	6.2
Core RoCE	11.2	10.5	5.1	10.2	17.7	6.7	4.8	8.0	10.6
RoIC	6.9	7.0	3.2	7.4	14.5	5.1	3.2	5.4	7.0
Working Capital Ratios	0.9	7.0	3.2	7.4	14.5	J.1	3.2	J. <del>4</del>	7.0
Fixed Asset Turnover (x)	0.7	0.6	0.6	0.7	0.8	0.7	0.6	0.6	0.6
Asset Turnover (x)	0.7	0.5	0.4	0.7	0.6	0.7	0.5	0.5	0.5
Inventory (Days)	315	347	257	317	282	341	324	300	290
Debtor (Days)	51	56	50	56	57	45	46	48	48
Creditor (Days)	269	302	256	338	289	320	318	290	290
Leverage Ratio (x)	209	302	230	336	203	320	310	230	250
Current Ratio	1.7	1.5	1.4	1.5	1.3	1.3	1.2	1.2	1.3
Interest Cover Ratio	3.4	3.8	2.0	4.9	7.2	3.5	1.7	3.0	6.9
Net Debt/Equity	0.2	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.1
Net Debt/Equity	0.2	0.5	0.5	0.2	0.2	0.2	0.2	0.2	0.1
Consolidated Cash Flow Statement									(INIDIA)
Consolidated - Cash Flow Statement Y/E March	EV40	FV20	EV24	FV22	EVOO	F)/2.4	FV2F	FV2CE	(INRb)
	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
OP/(Loss) before Tax  Depreciation	17.3 5.7	12.5 6.7	6.1	14.5	27.4	16.2	6.2	12.3	19.8
·	3.7		7.6	8.1	8.9	9.8	11.2	11.7	12.3
Interest & Finance Charges		0.3	1.3	0.5	1.9	2.4	3.4	2.0	-0.2
Direct Taxes Paid	-4.8	-2.2	-2.0	-2.7	-4.1	-3.8	-1.7	-2.7	-4.8
(Inc)/Dec in WC	-2.1	0.5	7.3	-6.1	-6.8	8.4	2.5	-0.3	1.2
CF from Operations	19.7	17.8	20.4	14.3	27.4	33.1	21.6	22.9	28.3
Others	-3.9	0.0	0.0	-0.3	2.4	-7.9	0.3	1.5	1.2
CF from Operating incl EO	15.8	17.8	20.4	14.1	29.7	25.2	21.9	24.4	29.5
(Inc)/Dec in FA	-10.8	-22.0	-8.9	-21.6	-27.3	-15.6	-25.6	-10.0	-5.0
Free Cash Flow	5.0	-4.2	11.5	-7.6	2.4	9.6	-3.7	14.4	24.5
(Pur)/Sale of Investments	-19.7	13.4	-15.6	-18.7	2.0	-22.8	6.0	0.0	0.0
Others	10.9	-15.1	13.2	31.9	11.1	32.3	-2.1	2.8	3.0
CF from Investments	-19.6	-23.7	-11.3	-8.4	-14.3	-6.1	-21.7	-7.2	-2.0
Issue of Shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inc/(Dec) in Debt	-5.7	12.6	-7.7	0.9	-7.3	-7.3	7.4	-8.5	-14.4
Interest Paid	-2.9	-3.4	-3.7	-3.0	-4.1	-5.3	-5.6	-4.7	-2.8
Dividend Paid	-6.7	-3.4	-3.1	-3.9	-4.5	-3.8	-2.8	-3.2	-3.8
Others	-6.2	1.4	-1.3	-0.7	-6.1	-2.8	0.5	0.0	0.0
CF from Fin. Activity	-21.5	7.2	-15.8	-6.7	-21.9	-19.3	-0.5	-16.5	-21.1
Inc/Dec of Cash	-25.3	1.3	-6.7	-1.0	-6.5	-0.2	-0.3	0.7	6.4
Opening Balance	44.8	19.5	20.8	14.1	13.1	6.7	6.4	6.2	6.9
Closing Balance	19.5	20.8	14.1	13.1	6.7	6.4	6.2	6.9	13.3

Investment in securities market are subject to market risks. Read all the related documents carefully before investing



Explanation of Investment Rating						
Investment Rating	Expected return (over 12-month)					
BUY	>=15%					
SELL	<-10%					
NEUTRAL	< - 10 % to 15%					
UNDER REVIEW	Rating may undergo a change					
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation					

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend. Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views. Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions. For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motifal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motifal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong. For U.S.

Motifial Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer,

MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL.

write to grievances@motilaloswal.com

#### Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

#### Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.

  MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research
  - Report:No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months. 3. MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report. MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- 6
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.

  MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.

  MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies)
- 8. in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

26 July 2025 11



financial interest in the subject company

actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

received compensation/other benefits from the subject company in the past 12 months any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services. Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures. Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products. Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.

26 July 2025 12